Description
Amiselimod, formerly known as MT-1303, is a prodrug that is converted to (S)-amiselimod phosphate by sphingosine kinases. And it also is a potent and selective immunosuppressant and sphingosine 1 phosphate receptor modulator, as an investigational therapy for people with relapsing-remitting muscular sclerosis (RRMS), inflammatory bowel disease (IBD), and other autoimmune diseases